Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase pin1

Molecular and Cellular Biology

Volumn 32, Issue 2, 2012, Pages 445-457

  Rajbhandari, Prashant ^a   Finn, Greg ^b   Solodin, Natalia M ^a   Singarapu, Kiran K ^c   Sahu, Sarata C ^c   Markley, John L ^a   Kadunc, Kelley J ^a   Ellison Zelski, Stephanie J ^a   Kariagina, Anastasia ^d   Haslam, Sandra Z ^d   Lu, Kun Ping ^b   Alarid, Elaine T ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIS TRANS ISOMERASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; PEPTIDYLPROLYL ISOMERASE PIN1; PROLINE; SERINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CATALYSIS; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME BINDING; IN VITRO STUDY; ISOMER; ISOMERIZATION; MUTATION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TRANSACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84856785971     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06073-11     Document Type: Article

References (105)

1. Acevedo ML, Lee KC, Stender JD, Katzenellenbogen BS, Kraus WL. 2004. Selective recognition of distinct classes of coactivators by a ligandinducible activation domain. Mol. Cell 13:725-738.
2. Ali S, Metzger D, Bornert JM, Chambon P. 1993. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 12:1153-1160.
3. Atsriku C, et al. 2009. Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol. Cell. Proteomics 8:467-480.
4. Bartels C, Xia T-H, Billeter M, Güntert P, Wüthrich K. 1995. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J. Biomol. NMR 6:1-10.
5. Berry M, Metzger D, Chambon P. 1990. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:2811-2818.
6. Bocchinfuso WP, Korach KS. 1997. Estrogen receptor residues required for stereospecific ligand recognition and activation. Mol. Endocrinol. 11:587-594.
7. Borras M, et al. 1996. Estrogenic and anti-estrogenic regulation of halflife of covalently labeled estrogen receptor in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 57:203-216.
8. Britton DJ, et al. 2006. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat. 96:131-146.
9. Brondani V, Schefer Q, Hamy F, Klimkait T. 2005. The peptidyl-prolyl isomerase Pin1 regulates phospho-Ser77 retinoic acid receptor alpha stability. Biochem. Biophys. Res. Commun. 328:6-13.
10. Brzozowski AM, et al. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758.
11. Bunone G, Briand PA, Miksicek RJ, Picard D. 1996. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174-2183.
12. Calligé M, Kieffer I, Richard-Foy H. 2005. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptorα by the proteasome. Mol. Cell. Biol. 25:4349-4358.
13. Castles CG, Oesterreich S, Hansen R, Fuqua SA. 1997. Auto-regulation of the estrogen receptor promoter. J. Steroid Biochem. Mol. Biol. 62: 155-163.
14. Chen D, et al. 2000. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell 6:127-137.
15. Cheng J, Zhang C, Shapiro DJ. 2007. A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxytamoxifen. Endocrinology 148:4634-4641.
16. Clarke RB, Howell A, Potten CS, Anderson E. 1997. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57:4987-4991.
17. Couse JF, Korach KS. 1999. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20:358-417.
18. Delaglio F, et al. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6:277-293.
19. Dowsett M, et al. 2010. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28:509-518.
20. Duplessis TT, Koterba KL, Rowan BG. 2009. Detection of ERα-SRC-1 interactions using bioluminescent resonance energy transfer. Methods Mol. Biol. 590:253-263.
21. Duplessis TT, Williams CC, Hill SM, Rowan BG. 2011. Phosphorylation of estrogen receptor alpha at serine 118 directs recruitment of promoter complexes and gene-specific transcription. Endocrinology 152: 2517-2526.
22. Dyson HJ, Wright PE. 2005. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6:197-208.
23. Early Breast Cancer Trialists' Collaborative Group. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717.
24. Einarson MB, Pugacheva EN, Orlinick JR. 2007. Far Western: probing membranes. Cold Spring Harb. Protoc. 2007. doi:10.1101/pdb.prot4759.
25. Ellison-Zelski SJ, Solodin NM, Alarid ET. 2009. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol. Cell. Biol. 29:4949-4958.
26. Endoh H, et al. 1999. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol. Cell. Biol. 19: 5363-5372.
27. Fabris G, et al. 1987. Pathophysiology of estrogen receptors in mammary tissue by monoclonal antibodies. J. Steroid Biochem. 27:171-176.
28. Faus H, Haendler B. 2006. Post-translational modifications of steroid receptors. Biomed. Pharmacother. 60:520-528.
29. Fila C, Metz C, van der Sluijs P. 2008. Juglone inactivates cysteine-rich proteins required for progression through mitosis. J. Biol. Chem. 283: 21714-21724.
30. Fowler AM, et al. 2004. Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J. 18:81-93.
31. Fujimoto Y, et al. 2010. Proline cis/trans-isomerase Pin1 regulates peroxisome proliferator-activated receptor gamma activity through the direct binding to the activation function-1 domain. J. Biol. Chem. 285: 3126-3132.
32. Gburcik V, Bot N, Maggiolini M, Picard D. 2005. SPBP is a phosphoserine-specific repressor of estrogen receptor alpha. Mol. Cell. Biol. 25:3421-3430.
33. Gburcik V, Picard D. 2006. The cell-specific activity of the estrogen receptor alpha may be fine-tuned by phosphorylation-induced structural gymnastics. Nucl. Recept. Signal. 4:e005.
34. Gutierrez MC, et al. 2005. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23:2469-2476.
35. Heldring N, et al. 2007. Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J. Biol. Chem. 282: 10449-10455.
36. Hennig L, et al. 1998. Selective inactivation of parvulin-like peptidylprolyl cis/trans isomerases by juglone. Biochemistry 37:5953-5960.
37. Henrich LM, et al. 2003. Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol. Cell. Biol. 23:5979-5988.
38. Ince BA, Zhuang Y, Wrenn CK, Shapiro DJ, Katzenellenbogen BS. 1993. Powerful dominant negative mutants of the human estrogen receptor. J. Biol. Chem. 268:14026-14032.
39. Jenster G, et al. 1997. Steroid receptor induction of gene transcription: a two-step model. Proc. Natl. Acad. Sci. U. S. A. 94:7879-7884.
40. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC. 1992. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol. Cell. Endocrinol. 90:77-86.
41. Kariagina A, Aupperlee MD, Haslam SZ. 2007. Progesterone receptor isoforms and proliferation in the rat mammary gland during development. Endocrinology 148:2723-2736.
42. Kariagina A, Xie J, Leipprandt JR, Halsam SZ. 2010. Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Hormones Cancer 1:229-244.
43. Kato S, et al. 1995. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494.
44. Kay L, Keifer P, Saarinen T. 1992. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J. Am. Chem. Soc. 114:10663-10665.
45. Knowlden JM, et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044.
46. Koterba KL, Rowan BG. 2006. Measuring ligand-dependent and ligandindependent interactions between nuclear receptors and associated proteins using bioluminescence resonance energy transfer (BRET). Nucl. Recept. Signal. 4:e021.
47. Kumar V, Chambon P. 1988. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145-156.
48. Lannigan DA. 2003. Estrogen receptor phosphorylation. Steroids 68: 1-9.
49. Lavery DN, McEwan IJ. 2005. Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem. J. 391:449-464.
50. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. 1994. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem. 269:4458-4466.
51. Lees JA, Fawell SE, White R, Parker MG. 1990. A 22-amino-acid peptide restores DNA-binding activity to dimerization-defective mutants of the estrogen receptor. Mol. Cell. Biol. 10:5529-5531.
52. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. 2006. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20:3120-3132.
53. Lim J, et al. 2008. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J. Clin. Invest. 118:1877-1889.
54. Lu KP, Finn G, Lee TH, Nicholson LK. 2007. Prolyl cis-trans isomerization as a molecular timer. Nat. Chem. Biol. 3:619-629.
55. Lu KP, Hanes SD, Hunter T. 1996. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380:544-547.
56. Lu KP, Liou YC, Zhou XZ. 2002. Pinning down proline-directed phosphorylation signaling. Trends Cell Biol. 12:164-172.
57. Lu KP, Zhou XZ. 2007. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. 8:904-916.
58. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. 1999. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:784-788.
59. Lykkesfeldt AE, Madsen MW, Briand P. 1994. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 54:1587-1595.
60. Mantovani F, et al. 2004. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol. Cell 14:625-636.
61. Markley JL, et al. 2009. The Center for Eukaryotic Structural Genomics J. Struct. Funct. Genomics 10:165-179.
62. Marsaud V, Gougelet A, Maillard S, Renoir J-M. 2003. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα) differentially affect ERα extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 17:2013-2027.
63. Masuhiro Y, et al. 2005. Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 102:8126-8131.
64. McInerney EM, Katzenellenbogen BS. 1996. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen-and estradiol-dependent transcription activation. J. Biol. Chem. 271:24172-24178.
65. McKenna NJ, Lanz RB, O'Malley BW. 1999. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20:321-344.
66. Medunjanin S, et al. 2005. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J. Biol. Chem. 280:33006-33014.
67. Murphy LC, Seekallu SV, Watson PH. 2011. Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer 18:R1-R14.
68. Namgoong GM, et al. 2010. The prolyl-isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J. Biol. Chem. 285:23829-23841.
69. Pakdel F, Reese JC, Katzenellenbogen BS. 1993. Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol. Endocrinol. 7:1408-1417.
70. Pons M, Gagne D, Nicolas JC, Mehtali M. 1990. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 9:450-459.
71. Powell E, Xu W. 2008. Intermolecular interactions identify ligandselective activity of estrogen receptor alpha/beta dimers. Proc. Natl. Acad. Sci. U. S. A. 105:19012-19017.
72. Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, Alarid ET. 2010. Proteasome inhibition represses ERα gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 29:1509-1518.
73. Ramelot TA, Nicholson LK. 2001. Phosphorylation-induced structural changes in the amyloid precursor protein cytoplasmic tail detected by NMR. J. Mol. Biol. 307:871-884.
74. Ranganathan R, Lu KP, Hunter T, Noel JP. 1997. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89:875-886.
75. Ring A, Dowsett M. 2004. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11:643-658.
76. Rochette-Egly C. 2003. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell. Signal. 15:355-366.
77. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. 2001. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 3:793-801.
78. Ryo A, et al. 2003. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12:1413-1426.
79. Sarkar P, Reichman C, Saleh T, Birge RB, Kalodimos CG. 2007. Proline cis-trans isomerization controls autoinhibition of a signaling protein. Mol. Cell 25:413-426.
80. Sarkar P, Saleh T, Tzeng SR, Birge RB, Kalodimos CG. 2011. Structural basis for regulation of the Crk signaling protein by a proline switch. Nat. Chem. Biol. 7:51-57.
81. Sarwar N, et al. 2006. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression. Endocr. Relat. Cancer 13:851-861.
82. Schutkowski M, et al. 1998. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry 37:5566-5575.
83. Schwabe JW, Chapman L, Finch JT, Rhodes D. 1993. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75: 567-578.
84. Shaaban AM, Sloane JP, West CR, Foster CS. 2002. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am. J. Pathol. 160:597-604.
85. Shiau AK, et al. 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
86. Stanya KJ, Liu Y, Means AR, Kao HY. 2008. Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J. Cell Biol. 183:49-61.
87. Suizu F, Ryo A, Wulf G, Lim J, Lu KP. 2006. Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol. Cell. Biol. 26:1463-1479.
88. Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA. 2002. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Mol. Endocrinol. 16:2706-2719.
89. Tan X, et al. 2010. Pin1 expression contributes to lung cancer: prognosis and carcinogenesis. Cancer Biol. Ther. 9:111-119.
90. Tora L, et al. 1989. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487.
91. Valley CC, et al. 2005. Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol. Cell. Biol. 25:5417-5428.
92. Warnmark A, Wikstrom A, Wright AP, Gustafsson JA, Hard T. 2001. The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties. J. Biol. Chem. 276:45939-45944.
93. Watanabe M, et al. 2001. A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J. 20:1341-1352.
94. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM. 1997. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138:4030-4033.
95. Weigel NL, Moore NL. 2007. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol. Endocrinol. 21: 2311-2319.
96. Weigel NL, Zhang Y. 1998. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76:469-479.
97. Werner-Allen JW, et al. 2011. cis-Proline-mediated Ser(P)5 dephosphorylation by the RNA polymerase II C-terminal domain phosphatase Ssu72. J. Biol. Chem. 286:5717-5726.
98. Wulf G, Finn G, Suizu F, Lu KP. 2005. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat. Cell Biol. 7:435-441.
99. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. 2002. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. 277:47976-47979.
100. Wulf GM, et al. 2001. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20:3459-3472.
101. Yaffe MB, et al. 1997. Sequence-specific and phosphorylationdependent proline isomerization: a potential mitotic regulatory mechanism. Science 278:1957-1960.
102. Yi P, et al. 2005. Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol. Cell. Biol. 25:9687-9699.
103. Zhang J, Socolovsky M, Gross AW, Lodish HF. 2003. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood 102: 3938-3946.
104. Zheng H, et al. 2002. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419:849-853.
105. Zhou XZ, et al. 2000. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell 6:873-883.